The Chinese University of Hong Kong has announced plans to advance its Just-in-time Adaptive Intervention (JITAI) for sleep and circadian problems into Phase III clinical trials. This randomized study seeks to evaluate the safety and performance of the optimized JITAI, known as GoodShleep+, which is built on the proven foundation of TranS-C behavioral therapy. The trial is not yet recruiting participants as of December 12, 2025. Stakeholders in clinical, quality, and regulatory processes should remain informed about this progress.
In this article
- What changed?
- What is GoodShleep+?
- Are there regulatory considerations?
- FAQ
- Conclusion
- Disclaimer
- Full announcement
What changed?
The optimization and evaluation of GoodShleep+, a behavioral intervention targeting sleep and circadian problems, have progressed to Phase III clinical trials. The intervention leverages JITAI technology to provide tailored, prompt support based on patients’ data and behavior. The academic sponsor, the Chinese University of Hong Kong, aims to ensure the intervention’s efficacy by aligning with regulatory frameworks and clinical validation processes.
What is GoodShleep+?
GoodShleep+ is an upgraded version of a Just-in-time Adaptive Intervention (JITAI) designed following the principles of TranS-C, a well-regarded behavioral therapy framework for sleep. The intervention uses adaptive algorithms to deliver therapeutic content at optimal times. By addressing sleep disruptions comprehensively, it integrates real-time data inputs for tailored user experiences.
The Phase III trial will test its optimized functionalities, emphasizing the safety and performance of the intervention under controlled conditions. For patients with chronic sleep and circadian challenges, the intervention may provide new opportunities to improve long-term outcomes while reducing reliance on pharmaceutical solutions.
Are there regulatory considerations?
The Phase III trial represents a critical milestone for GoodShleep+ from a regulatory perspective. Regulatory bodies, including those aligned with medical device guidelines, emphasize establishing scientific evidence for effectiveness and safety before widespread deployment. Moreover, the Chinese University of Hong Kong will conduct this study to ensure compliance with ethical, procedural, and legal requirements in medical research.
Quality and clinical teams should observe the Phase III documentation processes closely. The evidence generated by this study may influence how digital therapeutic interventions are regulated in global markets.
FAQ
- What is the current status of the trial?
The JITAI trial is not yet recruiting participants as of December 12, 2025. - Who is the sponsor?
This clinical study is sponsored by the Chinese University of Hong Kong. - What phase is this clinical trial in?
The GoodShleep+ intervention is currently planned for Phase III evaluation. - What are the intervention details?
It is based on tranS-C, a behavioral framework, and improved using JITAI technologies designed to provide adaptive, real-time therapeutic support.
Conclusion
The announcement of this Phase III clinical trial highlights the potential for GoodShleep+ to address persistent sleep disturbances using real-time adaptive solutions. Stakeholders in regulatory, clinical, and quality roles should monitor its progress for significant developments in both the behavioral intervention and medical devices sector.
Disclaimer
This content is for informational purposes only. It does not constitute legal or medical advice. For compliance-related decisions, consult a qualified professional.
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07277049?term=medical+device